Loss of heterozygosity analysis in malignant gliomas. 2011

Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. mmizoguc@ns.med.kyushu-u.ac.jp

Despite recent advances in the diagnosis and treatment of glioblastomas, patient outcomes for these highly malignant tumors remain poor. Research into the molecular pathology of glioblastoma has uncovered various genetic changes that contribute to malignancy. Some of the identified molecular markers--such as loss of heterozygosity (LOH) on chromosome 1p/19q and chromosome 10, O6-methylguanine methyltransferase promoter hypermethylation, and mutation of isocitrate dehydrogenase-1--may help to predict patient outcomes. Indeed, LOH analysis is an effective approach to classify malignant gliomas. Genome-wide analyses have revealed that the extent and pattern of LOH regions may have important implications for the clinical course of the disease. As the genetic underpinnings of malignant gliomas are complex and varied, careful selection of the methods for genetic analysis in the clinic is important. The fundamental principles of each assay need to be understood to allow careful selection of practically useful methods. This review summarizes recent developments in the molecular analysis of malignant glioma.

UI MeSH Term Description Entries
D007521 Isocitrate Dehydrogenase An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41. NAD Isocitrate Dehydrogenase,Isocitrate Dehydrogenase (NAD+),Isocitrate Dehydrogenase-I,Dehydrogenase, Isocitrate,Dehydrogenase, NAD Isocitrate,Isocitrate Dehydrogenase I,Isocitrate Dehydrogenase, NAD
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002878 Chromosomes, Human, Pair 1 A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification. Chromosome 1
D002879 Chromosomes, Human, Pair 10 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 10
D002888 Chromosomes, Human, Pair 19 A specific pair of GROUP F CHROMOSOMES of the human chromosome classification. Chromosome 19
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
February 2009, BMC cancer,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
June 1994, Cancer genetics and cytogenetics,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
May 2001, Journal of cancer research and clinical oncology,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
June 2003, Neurology,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
March 1992, Cancer research,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
September 1993, Human genetics,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
June 1996, Genomics,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
July 1992, Genes, chromosomes & cancer,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
February 1995, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Masahiro Mizoguchi, and Daisuke Kuga, and Yanlei Guan, and Nobuhiro Hata, and Akira Nakamizo, and Koji Yoshimoto, and Tomio Sasaki
July 2000, Genes, chromosomes & cancer,
Copied contents to your clipboard!